Aeterna Zentaris logo
Aeterna Zentaris AEZS

Annual report 2024
added 02-21-2026

report update icon

Aeterna Zentaris Total Assets 2011-2026 | AEZS

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Aeterna Zentaris

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
35.1 M 23.7 M 27.8 M 80.1 M 37 M 20 M 25 M 22.2 M 31.7 M 47.4 M 47.4 M 59.2 M 67.7 M 75.4 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
80.1 M 20 M 42.8 M

Quarterly Total Assets Aeterna Zentaris

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - 76.3 M 80.1 M 82 M 84.4 M 87 M 37 M 32.3 M 17.7 M 19.6 M 20 M 21.5 M 20.8 M - 25 M - - - 22.2 M - - - 31.7 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
87 M 17.7 M 43.8 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
1.08 B $ 20.36 -1.64 % $ 2.57 B usaUSA
MorphoSys AG MorphoSys AG
MOR
2.03 B - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
16.1 M $ 0.81 -4.23 % $ 4.42 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
690 M $ 164.64 -1.05 % $ 8.19 B usaUSA
I-Mab I-Mab
IMAB
6.33 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
18.1 B - - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
12 M - -13.47 % $ 169 M franceFrance
AbCellera Biologics AbCellera Biologics
ABCL
1.36 B $ 3.7 -3.27 % $ 1.11 B canadaCanada
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
15.2 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
14.8 M - -18.52 % $ 27.3 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
3.11 B $ 8.53 -2.35 % $ 1.39 B britainBritain
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
45.6 M $ 18.0 0.61 % $ 864 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
180 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
1.51 B - - - russiaRussia
Certara Certara
CERT
1.56 B $ 7.28 3.19 % $ 1.17 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
396 M - 1052.0 % $ 415 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
11.6 M - 2.71 % $ 14 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
287 M - - $ 2.17 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
58.7 M $ 26.28 -2.16 % $ 704 M usaUSA
Acasti Pharma Acasti Pharma
ACST
72 M - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
149 M $ 1.01 -0.49 % $ 74.1 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
1.16 B - - $ 867 M germanyGermany
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
1.1 B $ 23.89 0.04 % $ 2.92 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
12 M - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
778 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
66.7 M - - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
47.1 M - 1.93 % $ 17.4 M usaUSA
Agenus Agenus
AGEN
314 M $ 3.22 -3.59 % $ 1.15 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
7.77 M - - $ 7.46 M israelIsrael
Akero Therapeutics Akero Therapeutics
AKRO
826 M - - $ 3.67 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
1.3 B $ 28.92 -0.96 % $ 1.68 B usaUSA
Champions Oncology Champions Oncology
CSBR
32.3 M $ 5.98 -1.48 % $ 81.7 M usaUSA
Advaxis Advaxis
ADXS
16.6 M - -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
279 M - 0.23 % $ 488 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
1.4 B - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
2.05 B - - - russiaRussia
Albireo Pharma Albireo Pharma
ALBO
302 M - -0.23 % $ 916 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
384 M $ 3.68 -3.16 % $ 116 M franceFrance
Alector Alector
ALEC
293 M $ 2.13 -3.62 % $ 219 M usaUSA
KalVista Pharmaceuticals KalVista Pharmaceuticals
KALV
251 M $ 15.77 -1.81 % $ 783 M britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
34.8 M - 3.16 % $ 1.9 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
62.2 M - 10.36 % $ 9.8 M usaUSA
Altimmune Altimmune
ALT
139 M $ 4.25 2.04 % $ 302 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
87.8 M - -13.85 % $ 16.1 M usaUSA
AlloVir AlloVir
ALVR
119 M - 4.14 % $ 49.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
423 M - - $ 2.91 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
5.74 M - -11.43 % $ 502 K usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
671 M $ 14.2 1.9 % $ 5.89 B irlandaIrlanda